From the beginning, AiCuris’ success has been the result of strong internal expertise leveraged by dynamic and fruitful collaborations.
AiCuris is constantly evaluating strategic partnerships and collaboration opportunities with biotech or pharmaceutical companies. Our focus is the out-licensing of projects after clinical proof-of-concept (PoC), though we remain open for exploratory discussions at an earlier stage e.g. interest in co-development of a given project or in joining efforts to develop compounds.
As proof of AiCuris’ success as world-class partner in the anti-infective field, in 2012 AiCuris entered into an exclusive worldwide license agreement for its portfolio of investigational medicines targeting Human Cytomegalovirus (HCMV), including Letermovir, with Merck & Co., USA (MSD).
From the beginning, AiCuris’ success has been the result of strong internal expertise leveraged by dynamic and fruitful collaborations. With its longstanding competence in anti-infectives and proven development capabilities, AiCuris is a qualified partner in the industry for drug discovery and the development of antiviral and antimicrobial therapeutics.
Our partnering strategy focuses on expanding our portfolio and accelerating our ability to deliver novel anti-infective therapies to patients worldwide.
AiCuris is constantly evaluating strategic partnerships and collaboration opportunities with biotech or pharmaceutical companies. In addition, we are always interested in new collaborations with innovative, science-driven organizations and academic institutions to develop the next resistant breaking antibiotic or anti-infective.
AiCuris’ broad partnering network and connections in anti-infective research
To further support new ideas and novel approaches, AiCuris has launched AiCubator, an innovative corporate incubator that provides long-term support for early research projects in anti-infectives.
AiCuris also pursues an active licensing strategy, seeking collaboration and licensing opportunities that complement our existing portfolio and research focus with pre-clinical and early clinical projects focused on infectious diseases and hospital acquired infections.
In 2012, AiCuris entered into a successful partnership with Merck & Co., USA (MSD), and granted an exclusive worldwide license for Letermovir, a first-in-class non-nucleoside cytomegalovirus (CMV) inhibitor acting via a novel mechanism. In 2017 Letermovir was approved in the USA for prevention of CMV infections in adult recipients of an allogeneic hematopoietic stem cell transplant followed by approvals in the EU, Switzerland, Canada and Japan.
If you or your company are interested in partnering opportunities, please contact us.